TBCRC 022: phase II trial of neratinib + capecitabine for patients (pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM)
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.